People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to…
Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine…